Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer

[1]  A. D'Amico,et al.  NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  James M. Hodge,et al.  A Population-Based Study of Genes Previously Implicated in Breast Cancer. , 2021, The New England journal of medicine.

[3]  Alexander Hanbo Li,et al.  Exome-wide evaluation of rare coding variants using electronic health records identifies new gene–phenotype associations , 2021, Nature Medicine.

[4]  E. Antonarakis,et al.  Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. , 2020, JCO oncology practice.

[5]  C. Higano,et al.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Alexander E. Lopez,et al.  Polygenic Risk of Psychiatric Disorders Exhibits Cross-trait Associations in Electronic Health Record Data From European Ancestry Individuals , 2020, Biological Psychiatry.

[7]  Anne E. Calvaresi,et al.  Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jianfeng Xu,et al.  Diagnosing hereditary cancer predisposition in men with prostate cancer , 2020, Genetics in Medicine.

[9]  Jonathan M. Mudge,et al.  Transcript expression-aware annotation improves rare variant interpretation , 2020, Nature.

[10]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[11]  F. Couch,et al.  Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry. , 2020, JCO precision oncology.

[12]  Shan Yang,et al.  Inherited DNA-repair gene mutations in African American men with prostate cancer , 2020, Oncotarget.

[13]  K. Cooney,et al.  Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. , 2020, European urology oncology.

[14]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[15]  F. Couch,et al.  Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. , 2019, JCO precision oncology.

[16]  R. Eeles,et al.  Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel , 2019, European urology.

[17]  Dustin N. Hartzel,et al.  A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes , 2019, Genetics in Medicine.

[18]  J. Kleijnen,et al.  A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer , 2019, International journal of oncology.

[19]  E. Schaeffer,et al.  Germline and Somatic Mutations in Prostate Cancer for the Clinician. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  A. Jemal,et al.  Cancer statistics for African Americans, 2019 , 2019, CA: a cancer journal for clinicians.

[21]  R. Nussbaum,et al.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines , 2019, JAMA oncology.

[22]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[23]  S. Ambs,et al.  Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population , 2018, Prostate Cancer and Prostatic Diseases.

[24]  John Garcia,et al.  Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing , 2018, The Prostate.

[25]  M. Dall’Era,et al.  Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men. , 2018, American journal of preventive medicine.

[26]  W. Isaacs,et al.  Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer , 2018, The Prostate.

[27]  K. Cooney,et al.  Rare germline mutations in African American men diagnosed with early‐onset prostate cancer , 2018, The Prostate.

[28]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[29]  Anne Lanceley,et al.  Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review , 2017, BMC Public Health.

[30]  K. Cooney,et al.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.

[31]  S. Fullerton,et al.  Genomics is failing on diversity , 2016, Nature.

[32]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[33]  C. Ayo,et al.  An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis , 2016, PloS one.

[34]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[35]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[36]  J. Powers,et al.  Adverse Events in Cancer Genetic Testing: The Third Case Series , 2014, Cancer journal.

[37]  Alexis Criscuolo,et al.  AlienTrimmer removes adapter oligonucleotides with high sensitivity in short-insert paired-end reads. Commentary on Turner (2014) Assessment of insert sizes and adapter content in FASTQ data from NexteraXT libraries , 2014, Front. Genet..

[38]  D. Petersen,et al.  Clinical Presentation of Prostate Cancer in Black South Africans , 2014, The Prostate.

[39]  T. Sellers,et al.  Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers , 2014, Clinical genetics.

[40]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[42]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[43]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[44]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[45]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[46]  O. Olopade,et al.  Disparities in genetic testing: thinking outside the BRCA box. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[48]  C. Boring,et al.  Cancer statistics for african americans , 1992, CA: a cancer journal for clinicians.